CoChat

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

Open access
Lopez-Vivanco, G., Salvador, J., Diez, R., López, D., De Salas-Cansado, M., Navarro, B., De la Haba-Rodríguez, J. · 2017 · Clinical and Translational Oncology

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

PURPOSE: To describe healthcare professional (HCP) and patient time and related costs associated with trastuzumab intravenous infusion (IV) and trastuzumab subcutaneous (SC) formulations in patients with HER2-positive early breast cancer. METHODS: This prospective, observational time, and motion study in three Spanish centers was run as a substudy of the PrefHer trial. We recorded active HCP time for trastuzumab SC and IV-related tasks and calculated HCP time as the mean sum of task times over 154 administrations (80 IV, 74 SC). We calculated mean patient infusion chair time and treatment room time. Staff costs were calculated using fully loaded salary costs based on Spanish salaries (€ 2012). RESULTS: The transition from trastuzumab IV to SC led to a 50% reduction in active HCP time [27.2 min (95% CI 21.8-32.6) vs. 13.2 min (95% CI 8.9-17.5) per cycle]. Time savings resulted from avoiding IV catheter installation and removal, line flushing, and drug reconstitution. SC administration led to a fivefold reduction (78-85%) in chair time and a fourfold reduction (59-81%) in patient treatment room time, resulting in 24 h free-up time in the total treatment course (18 cycles). Total estimated direct costs were € 29,431.75 and € 28,452.12 for IV and SC, respectively, a saving of € 979.60 over a full treatment course. CONCLUSIONS: Trastuzumab SC provided substantial time savings for HCP and patients, and reduced staff costs vs. trastuzumab IV. Reducing the use of hospital facilities may result in further savings and improved quality of medical care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12094-017-1684-4

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Tasks evaluated in the preparation area and treatment room
Fig. 1 Tasks evaluated in the preparation area and treatment roomCC BY · PubMed Central
Fig. 2 Active healthcare professional time in the tasks observed in the treatment room and the preparation area for all centers (a) and for each center (b) according to the route of administration
Fig. 2 Active healthcare professional time in the tasks observed in the treatment room and the preparation area for all centers (a) and for each center (b) according to the route of administrationCC BY · PubMed Central
Fig. 3 Difference between active times observed between trastuzumab SC and IV (time required for SC minus time required for IV)
Fig. 3 Difference between active times observed between trastuzumab SC and IV (time required for SC minus time required for IV)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 54

Metadata

Authors
Lopez-Vivanco, G., Salvador, J., Diez, R., López, D., De Salas-Cansado, M., Navarro, B., & De la Haba-Rodríguez, J.
Affiliations
  • Hospital Universitario de Valme (ES)
  • Hospital Universitario de Getafe (ES)
  • Roche (Spain) (ES)
Corresponding author
Navarro, B.
Venue
Clinical and Translational Oncology
Published
2017-06-02
Volume
19
Issue
12
Pages
1454-1461
ISSN
  • 1699-048X (ISSN-L)
  • 1699-3055
OpenAlex
W2621391008
Cited by
54
References
19
Citations by year
2026: 3 · 2025: 7 · 2024: 11 · 2023: 10 · 2022: 3 · 2021: 9 · 2020: 3 · 2019: 6 · 2018: 1 · 2017: 1
FWCI
5.41
Type
journal article
Language
en
Open access
Locations
  • Clinical & Translational Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
Funders
Roche Pharma
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
Keywords
trastuzumab, HER2-positive breast cancer, subcutaneous administration, intravenous infusion, cost minimization, personnel costs, time and motion study, early breast cancer
MeSH terms
Trastuzumab, Antineoplastic Agents, Breast Neoplasms, Costs and Cost Analysis, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Middle Aged, Prognosis, Prospective Studies, Spain, Erb-b2 Receptor Tyrosine Kinases, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. https://app.cochat.ai/papers/10.1007/s12094-017-1684-4
The paper
Lopez-Vivanco, G., Salvador, J., Diez, R., López, D., De Salas-Cansado, M., Navarro, B., & De la Haba-Rodríguez, J. (2017). Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-017-1684-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.